Reaction
Injection Site Hypersensitivity reporting signals
As of the last recalculation, Injection Site Hypersensitivity appears in 3,034 FAERS reports alongside 40 co-occurring drug terms. The strongest observed disproportionality signal is TIRZEPATIDE (PRR 28.2).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Tirzepatide | 548 | 28.2 | 28.3 |
| Anakinra | 65 | 27.4 | 27.6 |
| Fremanezumab-Vfrm | 33 | 19.9 | 20.0 |
| Octreotide Acetate | 68 | 15.6 | 15.6 |
| Ixekizumab | 77 | 14.6 | 14.7 |
| Galcanezumab-Gnlm | 63 | 14.0 | 14.0 |
| Asfotase Alfa | 20 | 13.8 | 13.8 |
| Inclisiran | 13 | 11.2 | 11.2 |
| Pegvaliase-Pqpz | 11 | 9.2 | 9.2 |
| Esomeprazole Magnesium Capsule, Delayed Release | 17 | 8.1 | 8.1 |
| Esomeprazole Magnesium Delayed Release Capsules | 17 | 8.1 | 8.1 |
| Esomeprazole Magnesium Dihydrate | 17 | 8.0 | 8.1 |
| Peginterferon Beta-1A | 15 | 7.9 | 7.9 |
| Tocilizumab | 109 | 6.8 | 6.8 |
| Alirocumab | 24 | 6.6 | 6.6 |
| Sarilumab | 25 | 6.5 | 6.5 |
| Etanercept | 490 | 6.5 | 6.5 |
| Glatiramer Acetate | 54 | 6.3 | 6.3 |
| Naltrexone | 28 | 6.3 | 6.3 |
| Dulaglutide | 74 | 5.8 | 5.8 |
| Romosozumab-Aqqg | 11 | 5.6 | 5.6 |
| Leflunomide | 79 | 5.3 | 5.3 |
| Insulin Glulisine | 7 | 4.7 | 4.7 |
| Everolimus | 34 | 4.6 | 4.6 |
| Liraglutide | 30 | 4.2 | 4.2 |
| Sunitinib Malate | 22 | 3.9 | 3.9 |
| Omalizumab | 46 | 3.7 | 3.7 |
| Abaloparatide | 16 | 3.7 | 3.7 |
| Adalimumab | 344 | 3.6 | 3.6 |
| Onabotulinumtoxina | 31 | 2.8 | 2.8 |
| Exenatide | 20 | 2.6 | 2.6 |
| Evolocumab | 59 | 2.5 | 2.5 |
| Interferon Beta-1B | 7 | 2.5 | 2.5 |
| Erenumab-Aooe | 20 | 2.5 | 2.5 |
| Tofacitinib | 63 | 2.4 | 2.4 |
| Leuprolide Acetate | 26 | 2.3 | 2.3 |
| Botulinum Toxin Type A | 4 | 2.2 | 2.2 |
| Dupilumab | 145 | 2.1 | 2.1 |
| Rimegepant Sulfate | 3 | 1.6 | 1.6 |
| Bimekizumab | 5 | 1.6 | 1.6 |